Cancer Cell
Volume 33, Issue 1, 8 January 2018, Pages 3-5
Journal home page for Cancer Cell

Preview
BET’ing on Dual JAK/BET Inhibition as a Therapeutic Strategy for Myeloproliferative Neoplasms

https://doi.org/10.1016/j.ccell.2017.12.007Get rights and content
Under an Elsevier user license
open archive

In this issue of Cancer Cell, Kleppe et al. describe a combination strategy designed to inhibit BET bromodomain and JAK/STAT signaling as a method for effectively inhibiting NF-κB and cytokine production in myeloproliferative neoplasms (MPNs). The results provide a strong rationale for clinical evaluation of dual BET/JAK inhibition in MPNs.

Cited by (0)